New Risk • Jun 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr47m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 4.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Market cap is less than US$10m (kr5.84m market cap, or US$632.8k). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Revenue is less than US$5m (kr11m revenue, or US$1.2m). Duyuru • Apr 01
ExpreS2ion Biotech Holding AB (publ) Approves Appointment of Michel J. Baijot as Board Member ExpreS2ion Biotech Holding AB (publ) at its EGM held on 1 April 2026 approved election of Michel J. Baijot as board member for the period until the end of the next Annual General Meeting. Thus, the board of directors, for the period until the end of the next Annual General Meeting, will consist of Martin Roland Jensen (chairman), Karin Garre, Jakob Knudsen and Michel J. Baijot. Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Member of Infectious Diseases Scientific Advisory Board Stanley Plotkin was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Duyuru • Mar 19
ExpreS2ion Biotech Holding AB (publ) to Report Fiscal Year 2025 Final Results on Jun 04, 2026 ExpreS2ion Biotech Holding AB (publ) announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Jun 04, 2026 Reported Earnings • Nov 14
Third quarter 2025 earnings released Third quarter 2025 results: Net loss: kr8.45m (loss narrowed 19% from 3Q 2024). New Risk • Oct 23
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 69% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr53m free cash flow). Earnings have declined by 10.0% per year over the past 5 years. Shareholders have been substantially diluted in the past year (69% increase in shares outstanding). Market cap is less than US$10m (kr65.7m market cap, or US$6.98m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (kr10m revenue, or US$1.1m). New Risk • Oct 15
New major risk - Revenue and earnings growth Earnings have declined by 10.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr53m free cash flow). Earnings have declined by 10.0% per year over the past 5 years. Market cap is less than US$10m (kr51.0m market cap, or US$5.37m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding). Revenue is less than US$5m (kr10m revenue, or US$1.1m). Reported Earnings • Aug 22
Second quarter 2025 earnings released Second quarter 2025 results: Net loss: kr10.0m (down 495% from profit in 2Q 2024). Revenue is expected to decline by 15% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Sweden are expected to grow by 14%. Duyuru • Jul 03
ExpreS2ion Biotech Holding AB Announces Austrian Regulatory Green Light Enables ADC Combination Testing and Phase I Site Expansion for ES2B-C001, a First-in-Class Breast Cancer Immunotherapy ExpreS2ion Biotech Holding AB announced that the Austrian regulatory authorities have approved the Company's protocol amendment to evaluate its breast cancer immunotherapy candidate, ES2B-C001, in combination with HER2-targeted antibody-drug conjugates (ADCs) and to expand the number of trial sites. Filed on 13 May 2025, the amendment enables concurrent administration of ES2B-C001 alongside HER2-targeted ADCs (such as trastuzumab deruxtecan) in select patients and allows for an increase in the number of clinical trial sites in Austria. The Company had anticipated approval by mid-Q3 2025; this was received ahead of schedule on 30 June. The expanded protocol is expected to support improved patient recruitment. Duyuru • Jun 24
ExpreS2ion Biotech Holding AB Announces Dosing of First Patient in Phase I Clinical Trial of ES2B-C001, its Novel Therapeutic Breast Cancer Immunotherapy ExpreS2ion Biotech Holding AB announced that the first patient has been dosed in the Phase I clinical trial of ES2B-C001 (HER2-VLP), the company's novel therapeutic breast cancer immunotherapy candidate. The first patient was dosed with ES2B-C001, and it was well tolerated. The trial is being conducted in collaboration with the clinical staff at the Medical University of Vienna and investigates the safety and tolerability of ES2B-C002 in patients with metastatic HER2-expressing breast cancer. The Phase I study is designed as a First-in-Human trial to evaluate the safety and tolerability ofES2B-C001 with or without an adjuvant. Secondary objectives include the assessment of immunogenicity and the potential antibody activity of the vaccine. The study will enrol patients with HER2-expressing metastatic breast cancer who have progressed on or are refractory to standard HER2-targeted therapies. On 13 May 2025, ExpreS2ion filed a protocol amendment to optionally include concurrent administration of a HER2-targeted antibody-drug conjugate (such as trastuzumab deruxtecan) in select patients. The amendment also proposes an increase in the number of clinical trial sites in Austria. A response to this amendment is expected in Third Quarter 2025. To further support patient enrolment, referral pathways have been established through agreements with five clinics in Vienna, enabling referral of eligible patients to the active study site at the Medical University of Vienna. ES2B-C001 is a first-in-class therapeutic vaccine candidate targeting HER2-expressing cancers. It combines ExpreS2 protein expression platform with virus-like particle (VLP) technology developed by AdaptVac ApS. The vaccine is designed to elicit a broad polyclonal antibody response against multiple domains of the HER2 receptor, with the goal of overcoming resistance seen with current HER2-targeted monoclonal antibodies. Preclinical studies, including those published by Ruzzi et al. (2022), have shown that ES2B-C001 significantly reduces tumour burden and improves survival in animal models. New Risk • May 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr56m free cash flow). Earnings are forecast to decline by an average of 5.9% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (107% increase in shares outstanding). Revenue is less than US$1m (kr9.2m revenue, or US$963k). Market cap is less than US$10m (kr62.7m market cap, or US$6.55m). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr38m net loss next year). Share price has been volatile over the past 3 months (13% average weekly change). Duyuru • May 16
ExpreS2ion Files Clinical Trial Amendment to Enable Combination Testing of ES2B-C001 with Antibody-Drug Conjugates and to Expand the Number of Study Sites ExpreS2ion Biotech Holding AB announced that it has submitted a study protocol amendment to the Austrian regulatory authorities to enable the evaluation of its breast cancer vaccine candidate, ES2B-C001, in combination with antibody-drug conjugates (ADCs) and to expand the number of study sites. HER2-targeting therapies are commonly administered in combination regimens for metastatic breast cancer. Demonstrating that ES2B-C001 is safe -- and potentially adds efficacy -- when combined with ESMO guideline recommended treatment regimens for advanced-stage breast cancer such as Enhertu®? (trastuzumab deruxtecan) could significantly enhance the commercial and licensing potential of ExpreS2ion's breast cancer program. This update to the phase I study protocol also supports broader patient eligibility and aligns with current treatment standards. While the combination trial was initially intended for the vaccine's later-phase clinical development, the recent approval of reimbursement of Enhertu®? by Austrian health authorities as a treatment for HER2-positive metastatic breast cancer creates an opportunity to accelerate the generation of these important data. This amendment also requests to increase the number of clinical trial sites in Austria. To further support patient enrolment, referral pathways have been expanded through agreements with five clinics in Vienna to directly refer eligible patients to the active study site. Upon approval, which is anticipated by mid-Q3 2025, ExpreS2ion anticipates that these protocol modifications will substantially accelerate recruitment for the ongoing Phase I trial. Importantly, the trial will recruit patients under the current protocol, and these amendments are not expected to change existing timelines. The Company remains on track to report interim safety and tolerability data from the first patient cohort in the ES2B-C001 Phase I study and will provide an update on timelines when the first patient has been dosed. ES2B-C001 (HER2-VLP) is an innovative therapeutic vaccine developed specifically for HER2-expressing cancers. This novel approach combines ExpreS2 production platform with AdaptVac's VLP technology, both of which have been proven in clinical Phase III. The HER2-VLP vaccine's design aims to stimulate a robust and durable polyclonal immune response against HER2-expressing tumours, offering a complementary strategy to current treatments. Preclinical studies, as highlighted by Ruzzi et al. (2022), have demonstrated the vaccine's safety and efficacy across multiple animal models, significantly inhibiting tumour growth and improving survival rates. By leveraging the patient's immune system, ES2 B-C001 addresses the complexities of HER2-expressing breast cancer, potentially offering enhanced therapeutic options and filling critical gaps in the current treatment landscape. Reported Earnings • May 15
First quarter 2025 earnings released First quarter 2025 results: Net loss: kr11.4m (loss narrowed 11% from 1Q 2024). Revenue is expected to decline by 7.9% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Sweden are expected to grow by 16%. Duyuru • Apr 25
ExpreS2ion Biotech Holding AB (publ), Annual General Meeting, May 28, 2025 ExpreS2ion Biotech Holding AB (publ), Annual General Meeting, May 28, 2025, at 10:30 W. Europe Standard Time. Location: mindpark, bredgatan 11, helsingborg Sweden Duyuru • Apr 03
ExpreS2ion Biotech Holding AB Provides Pipeline Update ExpreS2ion Biotech Holding AB provided an update on its clinical and preclinical development activities. As previously communicated, ExpreS2ion expected to dose the first patient in its ongoing Phase I clinical trial for the therapeutic HER2 cancer vaccine candidate, ES2B-C001, in the first quarter of 2025. The Company notes that slower-than-expected patient recruitment is not uncommon in early-stage clinical development. Importantly, the delay is not related to any safety or scientific concerns with the vaccine candidate. The Company continues to work diligently to facilitate enrolment, including exploring potential operational measures to accelerate recruitment. An update will be published immediately upon first patient dosing, in line with prior communication and applicable regulations. Following an internal strategic review, ExpreS2ion has decided not to pursue further development of its CMV (Cytomegalovirus) vaccine candidate, previously conducted in collaboration with Evaxion Biotech A/S. This decision reflects ExpreS2ion's focus on programs with the strongest fit to its proprietary technology platform and core strategic objectives. Ending development of this non-core program will contribute to improved resource allocation and an extended financial runway. All rights to the CMV vaccine candidate revert to Evaxion following the conclusion of the collaboration. Duyuru • Apr 01
Expres2ion Biotech Holding AB (Publ) Announces Executive Changes ExpreS2ion Biotech Holding AB (publ) announced that Dr. Max Søgaard is promoted to Chief Science Officer, effective 1 April, taking over from Dr. Farshad Guirakhoo, who will continue in a consulting role as Senior Strategic Advisor Vaccine R&D. Dr. Max Søgaard joined ExpreS2ion in 2013 and has been instrumental in advancing ExpreS2ion's proprietary S2 technology ExpreS2, helping it reach its current status as a novel Phase III-proven platform. Most recently serving as Senior Vice President R&D and Technology, his leadership has been critical in the shaping the company's R&D strategy and pipeline. Reported Earnings • Feb 07
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: kr17.34 loss per share (improved from kr79.22 loss in FY 2023). Net loss: kr36.4m (loss narrowed 60% from FY 2023). Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) also missed analyst estimates by 41%. Revenue is forecast to grow 1.1% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Biotechs industry in Sweden. Duyuru • Dec 18
ExpreS2ion Biotech Holding AB (publ) to Report Fiscal Year 2025 Final Results on May 02, 2026 ExpreS2ion Biotech Holding AB (publ) announced that they will report fiscal year 2025 final results on May 02, 2026 Major Estimate Revision • Nov 24
Consensus EPS estimates upgraded to kr0.38 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -kr15.29 to -kr0.383 per share. Revenue forecast unchanged from kr8.00m at last update. Biotechs industry in Sweden expected to see average net income growth of 28% next year. Consensus price target of kr303 unchanged from last update. Share price fell 12% to kr19.24 over the past week. Reported Earnings • Nov 17
Third quarter 2024 earnings released Third quarter 2024 results: Net loss: kr10.5m (loss narrowed 40% from 3Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 17% growth forecast for the Biotechs industry in Sweden. Reported Earnings • Aug 16
Second quarter 2024 earnings released Second quarter 2024 results: Net income: kr2.54m (up kr32.6m from 2Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 17% growth forecast for the Biotechs industry in Sweden. Duyuru • Aug 06
Expres2ion Submits Clinical Trial Application (CTA) to Conduct Phase I Study of ES2B-C001, an Innovative Therapeutic Breast Cancer Vaccine ExpreS2ion Biotech Holding AB (publ) announce the submission of ExpreS2ion’s first CTA, to the Austrian Agency for Health and Food Safety (BASG/AGES) for its novel therapeutic candidate, ES2B-C001 against breast cancer. This submission marks an important milestone in the company’s objective to address significant unmet medical needs in oncology. ES2B-C001 is a first-in-class therapeutic HER2-VLP based breast cancer vaccine designed to generate a strong and durable polyclonal immune response by presenting the entire extracellular domain of human HER2 protein on the surface of virus like particles (HER2-VLP). The submission follows a series of successful preclinical safety and efficacy studies in animal models for breast cancer vaccine. In vitro data obtained with sera from vaccinated animals demonstrated ES2B-C001's potential to overcome resistance to the current immunotherapies used as standard of care inhibiting tumour cell growth, which could in-turn extend and improve patients’ quality of life. The planned Phase I clinical trial will evaluate the safety, tolerability, maximum tolerated dose, immunogenicity, and preliminary efficacy of ES2B-C001, alone or in combination with the adjuvant Montanide, in women suffering from HER2 expressing breast cancer. The trial will be conducted at Medical University of Vienna, in Austria. ExpreS2ion has a strong track record of innovation. Several achievements lead up to this submission: ES2B-C001 platform technologies, ExpreS2™ and VLPs, are validated in Phase III clinical trials, Completion of proof-of-concept studies and safety studies in two mammalian species, Manufacture and release of drug product, Selection of phase I clinical trial site (Medical University of Vienna) and supporting CROs, Scientific advice meeting with BASG/AGES in Austria, Finalization of phase I clinical trial protocol. Major Estimate Revision • Jul 12
Consensus EPS estimates upgraded to kr0.38 loss, revenue downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from kr8.50m to kr8.00m. 2024 losses expected to reduce from -kr0.973 to -kr0.38 per share. Biotechs industry in Sweden expected to see average net income growth of 15% next year. Consensus price target of kr8.00 unchanged from last update. Share price fell 4.1% to kr1.07 over the past week. Board Change • Jun 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Karin Garre was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 17
First quarter 2024 earnings released First quarter 2024 results: Net loss: kr12.9m (loss narrowed 51% from 1Q 2023). Revenue is forecast to grow 4.8% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Biotechs industry in Sweden. Duyuru • Apr 17
ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS announced the completion of the final report for the Good Laboratory Practice (GLP) safety study in non-human primates of the ES2B-C001 (HER2-VLP) breast cancer vaccine candidate. This significant milestone marks an important step towards enabling a clinical trial application. The Company is currently focusing on Good Manufacturing Practice (GMP) production and designing the Phase I clinical trial, with the aim to initiate the Phase I trial within the next year. New Risk • Apr 16
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr108.0m (US$9.92m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr103m free cash flow). Revenue is less than US$1m (kr8.8m revenue, or US$808k). Market cap is less than US$10m (kr108.0m market cap, or US$9.92m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr40m net loss in 2 years). Shareholders have been diluted in the past year (37% increase in shares outstanding). Reported Earnings • Feb 12
Full year 2023 earnings released: kr2.08 loss per share (vs kr3.38 loss in FY 2022) Full year 2023 results: kr2.08 loss per share (improved from kr3.38 loss in FY 2022). Revenue: kr8.80m (up 43% from FY 2022). Net loss: kr96.0m (loss narrowed 19% from FY 2022). Products in clinical trials Phase I: 4 Phase II: 1 Phase III: 1 Revenue is expected to decline by 1.7% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Sweden are expected to grow by 18%. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings. Duyuru • Feb 08
ExpreS2ion Biotech Holding AB (publ), Annual General Meeting, May 23, 2024 ExpreS2ion Biotech Holding AB (publ), Annual General Meeting, May 23, 2024. Recent Insider Transactions • Dec 20
Chairman of the Board recently sold kr81k worth of stock On the 14th of December, Martin Jensen sold around 25k shares on-market at roughly kr3.25 per share. This transaction amounted to 4.1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Martin's only on-market trade for the last 12 months. Major Estimate Revision • Dec 05
Consensus revenue estimates increase by 13%, EPS downgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from kr8.00m to kr9.00m. EPS estimate fell from -kr1.35 to -kr2.21 per share. Biotechs industry in Sweden expected to see average net income growth of 5.7% next year. Consensus price target of kr9.00 unchanged from last update. Share price rose 313% to kr4.60 over the past week. Reported Earnings • Nov 17
Third quarter 2023 earnings released Third quarter 2023 results: Net loss: kr21.8m (loss narrowed 29% from 3Q 2022). Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings. Duyuru • Sep 28
ExpreS2ion Biotech Holding AB Announces Changes to Leadership Team ExpreS2ion Biotech Holding AB announced that Dr. Mattis Ranthe, Chief Medical Officer, and Dr. Mette Thorn, Senior Vice President of Preclinical Development, are stepping down from their positions in the Company following the future strategic focus on ExpreS2ion's exploratory vaccine pipeline and technology platforms, as announced on 17 August 2023. Dr. Ranthe will continue supporting the Company through the end of 2023 to ensure the transition of his responsibilities. Dr. Thorn's last day is 29 September 2023, and her responsibilities will be covered by internal resources. Recent Insider Transactions Derivative • Sep 15
Chief Executive Officer exercised options to buy kr147k worth of stock. On the 13th of September, Bent Frandsen exercised options to buy 94k shares at a strike price of around kr1.57, costing a total of kr147k. This transaction amounted to 23% of their direct individual holding at the time of the trade. Since March 2023, Bent has owned 150.00k shares directly. Company insiders have collectively bought kr173k more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • Aug 18
Second quarter 2023 earnings released Second quarter 2023 results: Net loss: kr30.0m (loss widened 18% from 2Q 2022). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in Sweden. Reported Earnings • May 21
First quarter 2023 earnings released First quarter 2023 results: Net loss: kr26.3m (loss widened 90% from 1Q 2022). Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in Sweden. Reported Earnings • Feb 10
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: kr3.15 loss per share (further deteriorated from kr1.50 loss in FY 2021). Net loss: kr118.6m (loss widened 170% from FY 2021). Revenue missed analyst estimates by 49%. Earnings per share (EPS) also missed analyst estimates by 48%. Revenue is forecast to grow 48% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Duyuru • Jan 04
ExpreS2ion Biotech Holding AB Appoints Dr. Farshad Guirakhoo as Chief Scientific Officer, Effective January 16, 2023 ExpreS2ion Biotech Holding AB announced the appointment of Dr. Farshad Guirakhoo as the Company's new Chief Scientific Officer (CSO). Dr. Guirakhoo has more than 30 years of broad translational research experience in the vaccine development field, and will be responsible for directing the development of the discovery and preclinical strategies and plans that support ExpreS2ion's development pipeline of unique vaccine assets, including managing the progression of ExpreS2ion's vaccine technology platform. Dr. Guirakhoo starts his employment on January 16, 2023 at ExpreS2ion's headquarters in Hørsholm, Denmark. Dr. Farshad Guirakhoo joins from his recent positions as Senior Advisor Vaccine Research and Development and CSO of Vaxxinity Inc., which is headquartered in Dallas, Texas. In 2014, Dr. Guirakhoo was named as no. 22 in The Most Influential People in Vaccines. He is the co-inventor of the ChimeriVax-technology platform, the world's first recombinant viral vector platform that was approved for any human vaccine. Dr. Guirakhoo has broad experience in the application of genetics, gene expression technologies and molecular virology for the construction and production of recombinant proteins, human antibodies and attenuated viral vectored vaccines for prevention and treatment of infectious diseases and cancers. He is the author of over 100 peer-reviewed publications and holds dozens of issued patents. Dr. Guirakhoo received his Ph.D. in Virology from the Medical University of Vienna, Austria, holds an M.Sc. in Genetics from the International Institute for Biophysics and Biochemistry at the University of Tehran and a B.Sc. in Biology from the National University of Iran. He has been awarded the National Research Council Post-Doctorate Award and studied at the CDC, Division of Vector-Borne Infectious Diseases, in Fort Collins, CO, United States. Reported Earnings • Nov 18
Third quarter 2022 earnings released Third quarter 2022 results: Net loss: kr30.7m (loss widened 227% from 3Q 2021). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 29% growth forecast for the Biotechs industry in Sweden. Price Target Changed • Nov 16
Price target decreased to kr25.00 Down from kr86.00, the current price target is provided by 1 analyst. New target price is 121% above last closing price of kr11.31. Stock is down 76% over the past year. The company is forecast to post a net loss per share of kr2.29 next year compared to a net loss per share of kr1.50 last year. Breakeven Date Change • Oct 11
No longer forecast to breakeven The analyst covering ExpreS2ion Biotech Holding no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr142.0m in 2023. New forecast suggests the company will make a loss of kr13.0m in 2024. Breakeven Date Change • Sep 23
No longer forecast to breakeven The analyst covering ExpreS2ion Biotech Holding no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr142.0m in 2023. New forecast suggests the company will make a loss of kr13.0m in 2024. Reported Earnings • Aug 19
Second quarter 2022 earnings released Second quarter 2022 results: Net loss: kr25.5m (loss widened 182% from 2Q 2021). Over the next year, revenue is forecast to grow 1,286%, compared to a 218% growth forecast for the Biotechs industry in Sweden. Recent Insider Transactions • Jul 05
Board Member recently sold kr105k worth of stock On the 28th of June, Allan Rosetzsky sold around 9k shares on-market at roughly kr12.00 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr630k more than they bought in the last 12 months. Reported Earnings • Jun 02
First quarter 2022 earnings: Revenues exceed analyst expectations First quarter 2022 results: Revenue: kr2.08m (up 7.6% from 1Q 2021). Net loss: kr13.8m (loss widened 24% from 1Q 2021). Revenue exceeded analyst estimates by 14%. Over the next year, revenue is forecast to grow 473%, compared to a 246% growth forecast for the industry in Sweden. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Jakob Knudsen was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Price Target Changed • Apr 09
Price target decreased to kr86.00 Down from kr99.00, the current price target is provided by 1 analyst. New target price is 483% above last closing price of kr14.75. Stock is down 70% over the past year. The company is forecast to post a net loss per share of kr3.74 next year compared to a net loss per share of kr1.50 last year. Major Estimate Revision • Mar 09
Consensus EPS estimates fall by 71% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from kr12.6m to kr12.0m. Losses expected to increase from kr2.19 per share to kr3.74. Biotechs industry in Sweden expected to see average net income growth of 23% next year. Consensus price target of kr99.00 unchanged from last update. Share price fell 22% to kr17.26 over the past week. Major Estimate Revision • Mar 03
Consensus EPS estimates fall by 71% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from kr12.6m to kr12.0m. Losses expected to increase from kr2.19 per share to kr3.74. Biotechs industry in Sweden expected to see average net income growth of 29% next year. Consensus price target up from kr88.00 to kr99.00. Share price rose 10% to kr20.50 over the past week. Reported Earnings • Feb 25
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: kr1.41 loss per share (up from kr1.83 loss in FY 2020). Revenue: kr13.7m (down 10.0% from FY 2020). Net loss: kr43.9m (loss widened 39% from FY 2020). Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 4.6%. Over the next year, revenue is expected to shrink by 8.2% compared to a 205% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 53% per year, which means it is well ahead of earnings. Duyuru • Feb 25
ExpreS2ion Biotech Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 09, 2023 ExpreS2ion Biotech Holding AB (publ) announced that they will report fiscal year 2022 results on Feb 09, 2023 Price Target Changed • Dec 08
Price target increased to kr79.00 Up from kr66.00, the current price target is provided by 1 analyst. New target price is 78% above last closing price of kr44.50. Stock is up 359% over the past year. The company is forecast to post a net loss per share of kr1.43 next year compared to a net loss per share of kr1.83 last year. Breakeven Date Change • Dec 08
Forecast breakeven date pushed back to 2023 The analyst covering ExpreS2ion Biotech Holding previously expected the company to break even in 2022. New forecast suggests the company will make a profit of kr144.0m in 2023. Average annual earnings growth of 103% is required to achieve expected profit on schedule. Reported Earnings • Nov 21
Third quarter 2021 earnings released: kr0.32 loss per share (vs kr0.30 loss in 3Q 2020) Third quarter 2021 results: Net loss: kr9.38m (loss widened 92% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 98% per year, which means it is well ahead of earnings. Reported Earnings • Aug 24
Second quarter 2021 earnings released: kr0.32 loss per share (vs kr0.27 loss in 2Q 2020) Second quarter 2021 results: Net loss: kr9.07m (loss widened 114% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 74% per year, which means it is well ahead of earnings. Recent Insider Transactions • Jul 06
Chief Financial Officer recently bought kr68k worth of stock On the 1st of July, Keith Alexander bought around 2k shares on-market at roughly kr38.66 per share. This was the largest purchase by an insider in the last 3 months. This was Keith's only on-market trade for the last 12 months. Recent Insider Transactions • Jul 04
Chief Financial Officer recently bought kr68k worth of stock On the 1st of July, Keith Alexander bought around 2k shares on-market at roughly kr38.66 per share. This was the largest purchase by an insider in the last 3 months. This was Keith's only on-market trade for the last 12 months. Executive Departure • Jun 03
Member of the Board of Directors Gitte Pedersen has left the company On the 26th of May, Gitte Pedersen's tenure as Member of the Board of Directors ended. We don't have any record of a personal shareholding under Gitte's name. Gitte is the only executive to leave the company over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Reported Earnings • May 22
First quarter 2021 earnings released First quarter 2021 results: Net loss: kr11.2m (loss widened 113% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 73% per year, which means it is well ahead of earnings. Reported Earnings • Feb 27
Full year 2020 earnings released: kr1.84 loss per share (vs kr1.27 loss in FY 2019) The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: kr15.3m (up 10% from FY 2019). Net loss: kr32.0m (loss widened 92% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 50% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 02
New 90-day high: kr18.50 The company is up 59% from its price of kr11.65 on 03 November 2020. The Swedish market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period. Is New 90 Day High Low • Jan 13
New 90-day high: kr14.00 The company is up 13% from its price of kr12.40 on 14 October 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 3.0% over the same period. Is New 90 Day High Low • Nov 30
New 90-day low: kr10.15 The company is down 26% from its price of kr13.70 on 01 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. Recent Insider Transactions • Nov 26
Member of the Board of Directors recently bought kr205k worth of stock On the 19th of November, Allan Rosetzsky bought around 18k shares on-market at roughly kr11.21 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr564k more in shares than they bought in the last 12 months. Is New 90 Day High Low • Oct 29
New 90-day low: kr11.15 The company is down 48% from its price of kr21.60 on 30 July 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. Is New 90 Day High Low • Oct 05
New 90-day low: kr12.75 The company is down 53% from its price of kr27.10 on 07 July 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. 
